Found LegitScript and Accreditation Status: Is Found Weight Loss Legit?

What Is Found and How Does Its Telehealth Model Work?

Found is a direct-to-consumer telehealth platform launched in 2019 that connects patients with licensed clinicians who can prescribe FDA-approved and compounded weight-loss medications. The company pairs prescriptions with behavioral coaching, nutrition guidance, and app-based tracking. It accepts some commercial insurance through a Blue Cross Blue Shield of Illinois partnership announced in 2023, which distinguishes it from many cash-only GLP-1 programs.

Medications Available Through Found

Found clinicians may prescribe several drug classes depending on a patient's medical history and BMI criteria:

• GLP-1 receptor agonists: semaglutide (brand Wegovy, Ozempic) and tirzepatide (brand Zepbound, Mounjaro)
• Non-GLP-1 options: bupropion-naltrexone (Contrave), topiramate, metformin, and phentermine in eligible states
• Compounded semaglutide and tirzepatide: sourced from 503A or 503B compounding pharmacies during brand-name shortages

The FDA placed semaglutide on its drug shortage list in 2022, which legally permitted compounding pharmacies to produce copies. As of early 2025, the FDA has moved to end most compounded semaglutide production following shortage resolution, a regulatory shift that directly affects platforms like Found. Patients receiving compounded versions should confirm their pharmacy's compliance status with FDA guidance. See FDA 503B outsourcing facility database.

Clinical Effectiveness of the Underlying Medications

The drugs Found prescribes carry strong trial evidence. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM 2021). SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced up to 20.9% mean weight loss at 72 weeks versus 3.1% placebo (Jastreboff et al., NEJM 2022). The platform itself does not manufacture these drugs, so its clinical value lies in access, prescriber quality, and ongoing monitoring rather than the pharmacology of the agents.

Found's LegitScript Certification Status

LegitScript certification is a third-party verification that an online pharmacy or telehealth platform meets standards for prescription drug dispensing, practitioner legitimacy, and regulatory compliance. Many health systems and payment processors require it.

What LegitScript Actually Checks

LegitScript evaluates whether a platform:

1. Employs licensed, verifiable prescribers
2. Dispenses medications only through state-licensed pharmacies
3. Requires a valid patient-prescriber relationship before issuing prescriptions
4. Complies with all applicable federal and state laws

A platform that passes these checks receives a "Certified" badge searchable in the LegitScript database. A platform that is not listed is either unapplied, under review, or has been declined.

Found's Status as of January 2025

As of January 2025, Found (Found Health, Inc.) does not appear in LegitScript's publicly searchable certified telehealth provider database. This absence does not by itself establish that Found is operating illegally. LegitScript certification is voluntary, not legally mandated. However, absence from the database means patients cannot use LegitScript as an independent quality signal for this platform.

Patients evaluating any telehealth weight-loss company should apply a four-point verification framework: (1) confirm all prescribers hold active, unrestricted licenses in the patient's state via the relevant state medical board database; (2) verify the dispensing pharmacy holds a valid state pharmacy license; (3) check whether the platform appears in the LegitScript database; (4) review the BBB complaint log for patterns in billing, prescription fulfillment, and cancellation. Found passes point (1) when individual prescriber licenses are checked and point (2) for its partner pharmacies, but does not currently satisfy point (3).

BBB Rating and Complaint Analysis

The Better Business Bureau profile for Found Health, Inc. Provides a structured record of consumer complaints, company responses, and resolution rates. BBB accreditation and BBB rating are separate things. A company can have a rating without being formally "accredited" (accreditation requires a paid BBB membership and adherence to BBB standards).

Current BBB Standing

Found's BBB profile shows a rating that has fluctuated between B and A- over the past 24 months. The exact current rating should be checked directly at bbb.org because it updates as complaints are resolved or filed. The raw complaint count is more informative than the letter grade. As of early 2025, Found has accumulated several dozen consumer complaints, which is notable for a subscription health service but not unusual compared to similar-scale telehealth platforms.

Most Common Complaint Categories

Reviewing the publicly available complaint descriptions on the BBB profile reveals three recurring patterns:

1. Billing disputes: Patients report being charged membership fees after cancellation requests, or charged for medications not received.
2. Prescription delays: Several complaints describe wait times of two to six weeks between consultation completion and prescription transmission to pharmacy.
3. Cancellation difficulty: Consumers report that canceling the Found subscription requires contacting customer service rather than self-service cancellation through the app, leading to unintended renewals.

These complaint categories do not indicate clinical malpractice. They point to operational and customer-service gaps. Still, billing transparency is a meaningful consumer-protection issue, particularly for patients on fixed incomes who depend on GLP-1 access.

State Attorney General Actions

No state attorney general enforcement action specifically against Found Health, Inc. Has been publicly documented as of January 2025. This is a meaningful data point. Several competing telehealth weight-loss platforms have faced state-level scrutiny over prescription practices and deceptive advertising, so Found's absence from enforcement records is a relative positive.

FDA and DEA Regulatory Compliance

GLP-1 medications do not carry an FDA Risk Evaluation and Mitigation Strategy (REMS) program, meaning there is no federally mandated patient registry or prescriber certification requirement. However, several other regulatory layers apply to any platform prescribing these drugs.

Compounded Drug Oversight

The FDA's authority over compounding pharmacies is defined by Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounded semaglutide is only legal when an FDA-recognized drug shortage exists and when the compounding pharmacy is properly registered. The FDA maintains a current shortage list that patients and clinicians can cross-reference. Found, like other platforms, must source compounded product only from compliant facilities. Patients should ask their Found clinician or support team for the specific pharmacy name and then verify that pharmacy's registration independently.

Prescriber Licensing and Ryan Haight Act Compliance

The Ryan Haight Online Pharmacy Consumer Protection Act requires that a prescriber either conduct an in-person evaluation or meet a DEA telehealth exception before prescribing controlled substances. Phentermine is Schedule IV. Found clinicians prescribing phentermine must therefore comply with Ryan Haight requirements, which typically means a prior in-person encounter or compliance with post-COVID DEA telehealth flexibilities. GLP-1 agonists are not controlled substances, so Ryan Haight does not apply to semaglutide or tirzepatide prescriptions. Patients in states where Found operates should confirm prescriber licensure through their state medical board's license lookup tool.

Insurance Coverage and BCBS Partnership

Found announced a partnership with Blue Cross Blue Shield of Illinois in 2023, making it one of the earlier telehealth weight-loss companies to secure an insurance agreement. Coverage under this arrangement applies to Illinois BCBS members and covers the Found membership fee, not necessarily the drug cost itself.

What the Insurance Covers

The BCBS partnership primarily covers access to the Found platform (the clinical consultation and coaching component). Drug coverage depends on the member's specific pharmacy benefit plan. Wegovy carries a separate insurance pathway and is not automatically covered simply because the Found membership is covered. Patients should call the member-services number on their BCBS card and ask specifically whether their formulary tier covers semaglutide 2.4 mg (Wegovy) before assuming full coverage.

Cash-Pay Pricing Without Insurance

Without insurance, Found charges a monthly membership fee in the range of $99 per month as of early 2025, which covers clinician consultations and coaching. Medication costs are separate. Compounded semaglutide through Found's partner pharmacies has been priced between $149 and $299 per month depending on dose. Brand-name Wegovy without manufacturer coupon averages over $1,300 per month at retail pharmacy. The Novo Nordisk savings card can reduce out-of-pocket cost to $0 for eligible commercially insured patients, a resource Found's care team should be proactively communicating to patients. (Novo Nordisk Wegovy savings information is available through the manufacturer's patient support program.)

Patient Safety Signals and Adverse Event Reporting

Found, like all telehealth prescribers, is obligated to counsel patients on GLP-1 adverse effects and to have a pathway for managing them. The FDA's MedWatch system allows patients and providers to report adverse events directly. The MedWatch portal is at fda.gov/safety/medwatch.

Known GLP-1 Adverse Effects Patients Should Discuss With Found Clinicians

The most common adverse effects of semaglutide and tirzepatide are gastrointestinal: nausea affects roughly 44% of patients on semaglutide 2.4 mg in STEP-1, and vomiting affects approximately 24% (Wilding et al., NEJM 2021). These effects typically peak in the first 12 weeks and attenuate with dose titration. More serious but rare risks include acute pancreatitis and, based on rodent data, a theoretical risk of thyroid C-cell tumors (which forms the basis for the boxed warning on both Wegovy and Ozempic). Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use GLP-1 agonists. A Found clinician should screen for these contraindications at intake; patients who are not asked about thyroid cancer history during their Found consultation should raise the question themselves.

Monitoring Requirements

The 2023 American Association of Clinical Endocrinologists (AACE) Obesity Clinical Practice Guidelines recommend quarterly monitoring of weight, blood pressure, heart rate, and metabolic labs during the first year of GLP-1 therapy. (AACE Obesity CPG, Endocr Pract 2023). Found's app-based check-ins may or may not constitute adequate clinical monitoring depending on whether a licensed clinician reviews the submitted data at each interval. Patients should confirm with their Found care team how often a physician or NP actively reviews their case, not just whether the app logs their weight.

How Found Compares to Other Telehealth Weight-Loss Platforms on Accreditation

Several competitor platforms have obtained LegitScript certification, including Hims and Hers Health and some independent online pharmacies. The National Association of Boards of Pharmacy (NABP) operates a separate ".pharmacy" domain accreditation and a "Not Recommended" site list. As of January 2025, Found does not appear on NABP's "Not Recommended" list, which is another modest positive signal.

Key Differentiators

• Prescriber model: Found uses a mix of employed and contracted clinicians; some competitors use only employed MDs.
• Non-GLP-1 options: Found's willingness to prescribe metformin and bupropion-naltrexone makes it more accessible to patients who do not qualify for or cannot afford GLP-1s.
• Insurance acceptance: The BCBS Illinois partnership is more developed than most competitor platforms, though it remains geographically limited.
• LegitScript gap: Hims and Hers and at least one other major competitor carry LegitScript certification that Found does not currently hold.

What Patients Should Verify Before Enrolling in Found

Before submitting payment information to Found or any telehealth weight-loss program, a patient should complete five specific checks.

1. Search the prescriber's name on the Federation of State Medical Boards DocInfo tool to confirm an active, unrestricted license in your state.
2. Ask Found's support team for the name of the dispensing pharmacy and then verify that pharmacy's license at NABP.
3. Search Found Health, Inc. On bbb.org and read the actual complaint text, not just the letter grade.
4. Confirm in writing whether your specific insurance plan covers the membership fee, the medication, or both.
5. Ask the clinician at intake whether they will actively review your labs and vitals at minimum every 90 days, in line with AACE 2023 guidance.

Found may or may not satisfy all five checks depending on when a patient enrolls and in which state. The AACE 2023 Obesity Clinical Practice Guidelines state: "Obesity is a chronic disease requiring long-term treatment and monitoring by a qualified clinician team," a standard against which any telehealth platform should be measured.